Dublin, Aug. 06, 2020 (GLOBE NEWSWIRE) -- The "Coronavirus Disease 2019 (COVID-19) - Analysis of the Emerging Disease Landscape - June 2020" report has been added to ResearchAndMarkets.com's offering.

The Epidemiology of COVID-19 is rapidly evolving and a number of companies have begun to invest in this space. The absence of proven therapeutic options and the lack of a vaccine to protect against infection has led to a race to develop effective interventions. A range of players - from pharma and biotech firms to academic institutions and government agencies - have thrown their hats in the ring.

Report Scope

• Global epidemiology metrics and trends
• Snapshot of epidemiological trends to date in the top three most-affected countries
• An overview of the pipeline for antivirals and vaccines
• Summary of available efficacy data
• An assessment of the clinical trials landscape by phase, sponsor type, geography, and other key attributes
• Highlights in deal-making trends, particularly public-private partnerships
• Spotlight on social media coverage

Reasons to Buy

• Understand the global epidemiology of COVID-19
• Obtain a snapshot of epidemiological trends to date in the top three most-affected countries
• Access an overview of the pipeline for therapeutics and vaccines
• Stay up to date on available efficacy data for pipeline-stage products
• View the clinical trials landscape by across key attributes
• Get up to speed on highlights in deal-making trends, particularly public-private partnerships
• Monitor top trends in social media coverage

Key Topics Covered

1 Executive Summary

2 Epidemiology
2.1 Epidemiology: Snapshot as of March 25, 2020
2.2 Epidemiology: Disease Trajectory as of March 25, 2020
2.3 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in China as of March 25, 2020
2.4 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in Italy as of March 25, 2020
2.5 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in the US as of March 25, 2020
2.6 Epidemiology Forecast: United States

3 Pipeline Overview
3.1 Pipeline Therapeutics: Breakdown by Phase
3.2 Pipeline Therapeutics: Breakdown by Molecule Type
3.3 Pipeline Therapeutics: Breakdown by Type of Developer
3.4 Pipeline Therapeutics: Clinical-Stage Candidates (Phase I - III)
3.5 Pipeline Therapeutics: Preclinical-Stage Candidates
3.6 Pipeline Therapeutics: Currently Available Data
3.7 Pipeline Vaccines: Breakdown by Phase
3.8 Pipeline Vaccines: Breakdown by Developer Type
3.9 Pipeline Vaccines: Clinical and Preclinical-Stage Candidates

4 Pipeline Overview
4.1 Pipeline Therapeutics: Breakdown by Phase
4.2 Pipeline Therapeutics: Breakdown by Molecule Type
4.3 Pipeline Therapeutics: Breakdown by Type of Developer
4.4 Pipeline Therapeutics: Clinical-Stage Candidates (Phase I - III)
4.5 Pipeline Therapeutics: Preclinical-Stage Candidates
4.6 Pipeline Therapeutics: Currently Available Data
4.7 Pipeline Vaccines: Breakdown by Phase
4.8 Pipeline Vaccines: Breakdown by Developer Type
4.9 Pipeline Vaccines: Clinical and Preclinical-Stage Candidates

5 Clinical Trials
5.1 Clinical Trials: Breakdown by Phase
5.2 Clinical Trials for Therapeutics and Vaccines
5.3 Clinical Trials: Overview by Region
5.4 Clinical Trials for Therapeutics: Leading Sponsors
5.5 Clinical Trials: Leading Industry Sponsors
5.6 Trends in Trial Design

6 Deal-making Trends
6.1 Deal-making Trends

7 Social Media Trends
7.1 Key Twitter Chatter
7.2 Top Trending Tweets include #Covid19 #Coronavirus #Patients #Flattenthecurve

8 Key Findings

For more information about this report visit https://www.researchandmarkets.com/r/sd97ui

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900